These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 31192580)
1. Co-Delivery of Natural Compounds with a Dual-Targeted Nanoparticle Delivery System for Improving Synergistic Therapy in an Orthotopic Tumor Model. Chu PY; Tsai SC; Ko HY; Wu CC; Lin YH ACS Appl Mater Interfaces; 2019 Jul; 11(27):23880-23892. PubMed ID: 31192580 [TBL] [Abstract][Full Text] [Related]
2. Multifunctional nanoparticles for targeting the tumor microenvironment to improve synergistic drug combinations and cancer treatment effects. Chen ML; Lai CJ; Lin YN; Huang CM; Lin YH J Mater Chem B; 2020 Dec; 8(45):10416-10427. PubMed ID: 33112350 [TBL] [Abstract][Full Text] [Related]
3. The Development of Hyaluronan/Fucoidan-Based Nanoparticles as Macrophages Targeting an Epigallocatechin-3-Gallate Delivery System. Ho CH; Chu PY; Peng SL; Huang SC; Lin YH Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32878305 [TBL] [Abstract][Full Text] [Related]
4. Synergistic effect of curcumin on epigallocatechin gallate-induced anticancer action in PC3 prostate cancer cells. Eom DW; Lee JH; Kim YJ; Hwang GS; Kim SN; Kwak JH; Cheon GJ; Kim KH; Jang HJ; Ham J; Kang KS; Yamabe N BMB Rep; 2015 Aug; 48(8):461-6. PubMed ID: 25441423 [TBL] [Abstract][Full Text] [Related]
5. Targeted intracellular protein delivery based on hyaluronic acid-green tea catechin nanogels. Liang K; Ng S; Lee F; Lim J; Chung JE; Lee SS; Kurisawa M Acta Biomater; 2016 Mar; 33():142-52. PubMed ID: 26785145 [TBL] [Abstract][Full Text] [Related]
6. Combination therapy with epigallocatechin-3-gallate and doxorubicin in human prostate tumor modeling studies: inhibition of metastatic tumor growth in severe combined immunodeficiency mice. Stearns ME; Amatangelo MD; Varma D; Sell C; Goodyear SM Am J Pathol; 2010 Dec; 177(6):3169-79. PubMed ID: 20971741 [TBL] [Abstract][Full Text] [Related]
8. Laminin receptor specific therapeutic gold nanoparticles (198AuNP-EGCg) show efficacy in treating prostate cancer. Shukla R; Chanda N; Zambre A; Upendran A; Katti K; Kulkarni RR; Nune SK; Casteel SW; Smith CJ; Vimal J; Boote E; Robertson JD; Kan P; Engelbrecht H; Watkinson LD; Carmack TL; Lever JR; Cutler CS; Caldwell C; Kannan R; Katti KV Proc Natl Acad Sci U S A; 2012 Jul; 109(31):12426-31. PubMed ID: 22802668 [TBL] [Abstract][Full Text] [Related]
9. (-)-Epigallocatechin gallate (EGCG)-nanoethosomes as a transdermal delivery system for docetaxel to treat implanted human melanoma cell tumors in mice. Liao B; Ying H; Yu C; Fan Z; Zhang W; Shi J; Ying H; Ravichandran N; Xu Y; Yin J; Jiang Y; Du Q Int J Pharm; 2016 Oct; 512(1):22-31. PubMed ID: 27544847 [TBL] [Abstract][Full Text] [Related]
10. Design and construction of IR780- and EGCG-based and mitochondrial targeting nanoparticles and their application in tumor chemo-phototherapy. Bao J; Zhao Y; Xu J; Guo Y J Mater Chem B; 2021 Dec; 9(48):9932-9945. PubMed ID: 34842269 [TBL] [Abstract][Full Text] [Related]
11. Effect of a prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate on the growth of androgen-independent prostate cancer in vivo. Lee SC; Chan WK; Lee TW; Lam WH; Wang X; Chan TH; Wong YC Nutr Cancer; 2008; 60(4):483-91. PubMed ID: 18584482 [TBL] [Abstract][Full Text] [Related]
12. Tumor-Homing Cell-Penetrating Peptide Linked to Colloidal Mesoporous Silica Encapsulated (-)-Epigallocatechin-3-gallate as Drug Delivery System for Breast Cancer Therapy in Vivo. Ding J; Yao J; Xue J; Li R; Bao B; Jiang L; Zhu JJ; He Z ACS Appl Mater Interfaces; 2015 Aug; 7(32):18145-55. PubMed ID: 26225796 [TBL] [Abstract][Full Text] [Related]
13. [Preparation, activity and targeting ability evaluation in vitro on folate mediated epigallocatechin-3-gallate albumin nanoparticles]. Zu YG; Yuan S; Zhao XH; Zhang Y; Zhang XN; Jiang R Yao Xue Xue Bao; 2009 May; 44(5):525-31. PubMed ID: 19618731 [TBL] [Abstract][Full Text] [Related]
14. Epigallocatechin Gallate/Layered Double Hydroxide Nanohybrids: Preparation, Characterization, and In Vitro Anti-Tumor Study. Shafiei SS; Solati-Hashjin M; Samadikuchaksaraei A; Kalantarinejad R; Asadi-Eydivand M; Abu Osman NA PLoS One; 2015; 10(8):e0136530. PubMed ID: 26317853 [TBL] [Abstract][Full Text] [Related]
15. Enhanced anti-colon cancer efficacy of 5-fluorouracil by epigallocatechin-3- gallate co-loaded in wheat germ agglutinin-conjugated nanoparticles. Wang R; Huang J; Chen J; Yang M; Wang H; Qiao H; Chen Z; Hu L; Di L; Li J Nanomedicine; 2019 Oct; 21():102068. PubMed ID: 31374249 [TBL] [Abstract][Full Text] [Related]
16. Targeting Tumor Cells with Nanoparticles for Enhanced Co-Drug Delivery in Cancer Treatment. Huang WY; Lai CH; Peng SL; Hsu CY; Hsu PH; Chu PY; Feng CL; Lin YH Pharmaceutics; 2021 Aug; 13(9):. PubMed ID: 34575403 [TBL] [Abstract][Full Text] [Related]
17. Targeted nanomedicine for prostate cancer therapy: docetaxel and curcumin co-encapsulated lipid-polymer hybrid nanoparticles for the enhanced anti-tumor activity in vitro and in vivo. Yan J; Wang Y; Zhang X; Liu S; Tian C; Wang H Drug Deliv; 2016 Jun; 23(5):1757-62. PubMed ID: 26203689 [TBL] [Abstract][Full Text] [Related]
18. Desirable PEGylation for improving tumor selectivity of hyaluronic acid-based nanoparticles via low hepatic captured, long circulation times and CD44 receptor-mediated tumor targeting. Teng C; Chai Z; Yuan Z; Ren L; Lin C; Yan Z; He W; Qin C; Yang L; Han X; Yin L Nanomedicine; 2020 Feb; 24():102105. PubMed ID: 31740406 [TBL] [Abstract][Full Text] [Related]
19. Targeted nanoparticles encapsulating (-)-epigallocatechin-3-gallate for prostate cancer prevention and therapy. Sanna V; Singh CK; Jashari R; Adhami VM; Chamcheu JC; Rady I; Sechi M; Mukhtar H; Siddiqui IA Sci Rep; 2017 Feb; 7():41573. PubMed ID: 28145499 [TBL] [Abstract][Full Text] [Related]
20. Co-delivery of docetaxel and curcumin prodrug via dual-targeted nanoparticles with synergistic antitumor activity against prostate cancer. Yan J; Wang Y; Jia Y; Liu S; Tian C; Pan W; Liu X; Wang H Biomed Pharmacother; 2017 Apr; 88():374-383. PubMed ID: 28122302 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]